Exhibit 99.1 MEREO BIOPHARMA GROUP PLC Condensed Consolidated Statements of Comprehensive (Loss)/Income (unaudited) | | | Six months | Six months | | --- | --- | --- | --- | | | | ended June 30, | ended June 30, | | | | 2022 | 2021 | | | Notes | £'000 | £'000 | | Revenue | 3 | — | 36,464 | | Cost of revenue | 3 | 352 | (18,137) | | Research and development expenses | | (13,322) | (9,858) | | Administrative expenses | | (8,840) | (8,673) | | Operating loss | | (21,810) | (204) | | Finance income | 4 | 173 | ...